ADAP Adaptimmune Therapeutics plc

4.01
-0.11  -3%
Previous Close 4.12
Open 4.19
Price To Book 1.7
Market Cap 419895994
Shares 104,712,218
Volume 111,700
Short Ratio
Av. Daily Volume 271,413

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Overall SPEAR program to be summaraized May 2, 2019 10:15 AM at ASGCT meeting.
MAGE-A4
Soild tumors
Initial safety data released at AACR April 2019.
AFP (ADP-A2AFP)
Hepatocellular carcinoma
Phase 1 data at ESMO noted no current response.
MAGE-A10
Non-Small Cell Lung Cancer (NSCLC)

Latest News

  1. Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
  2. These 3 Falling Knives Are Expected to Outperform
  3. Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
  4. Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
  5. Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price?
  6. Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT
  7. Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
  8. Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?
  9. Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
  10. Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
  11. Radius Exceeds 2018 Financial Guidance, Provides Updates
  12. Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
  13. Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
  14. What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own?
  15. Adaptimmune Announces that Gwen Binder will leave in January 2019
  16. Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  17. Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT
  18. uniQure Stock Rose 35.7% Yesterday—Here’s Why
  19. What You Must Know About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Financial Strength
  20. Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update